Best treatments for bcr-abl positive chronic myelogenous leukemia
5 products may treat bcr-abl positive chronic myelogenous leukemia, spanning FDA drug classes such as anthracycline topoisomerase inhibitor, kinase inhibitor, alkylating drug. The current highest-rated option is idarubicin hydrochloride. Ranked below by our independent recall-safety rating (rated where FDA data exists) — not medical advice; always consult a professional.
Quick answer: Of the 5 drugs we list for bcr-abl positive chronic myelogenous leukemia, none are yet flagged as generics in our price data, spanning classes such as anthracycline topoisomerase inhibitor, kinase inhibitor, alkylating drug. They’re ranked by each drug’s FDA recall-safety record — not clinical effectiveness for bcr-abl positive chronic myelogenous leukemia — so confirm the right choice with your prescriber.
Top-rated picks for bcr-abl positive chronic myelogenous leukemia: 1. Idarubicin Hydrochloride · 2. Idamycin Pfs · 3. Bosulif
| # | Drug | Rating | Type | Form | Class | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Injectable | Anthracycline Topoisomerase Inhibitor | No data | — | View → | |
| 2 | 64/100 | Prescription | Solution | Anthracycline Topoisomerase Inhibitor | No data | — | View → | |
| 3 | Not yet rated | Prescription | Capsule | Kinase Inhibitor | No data | — | View → | |
| 4 | Not yet rated | Prescription | Injectable | Alkylating Drug | No data | — | View → | |
| 5 | Not yet rated | Prescription | Tablet | Alkylating Drug | No data | — | View → |
Narrow by drug class
Explore the class hubs: alkylating drug · anthracycline topoisomerase inhibitor
Full ranking · 5 treatments
idarubicin hydrochloride
Boxed warningPrescriptionFDA-sourced
Idarubicin Hydrochloride is an anthracycline topoisomerase inhibitor used to treat Breast Neoplasms, Bcr-Abl Positive Chronic Myelogenous Leukemia, Acute Myeloid Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Price varies
idamycin pfs
Boxed warningPrescriptionFDA-sourced
Idamycin Pfs (Idarubicin Hydrochloride) is an anthracycline topoisomerase inhibitor used to treat Breast Neoplasms, Bcr-Abl Positive Chronic Myelogenous Leukemia, Acute Myeloid Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Price varies
bosulif
PrescriptionFDA-sourced
Bosulif (Bosutinib Monohydrate) is a kinase inhibitor used to treat Bcr-Abl Positive Chronic Myelogenous Leukemia.
Price varies
busulfex
PrescriptionFDA-sourced
Busulfex (Busulfan) is an alkylating drug used to treat Polycythemia Vera, Bcr-Abl Positive Chronic Myelogenous Leukemia, Primary Myelofibrosis.
Price varies
myleran
Boxed warningPrescriptionFDA-sourced
Myleran (Busulfan) is an alkylating drug used to treat Polycythemia Vera, Bcr-Abl Positive Chronic Myelogenous Leukemia, Primary Myelofibrosis.
Price varies
Frequently asked
- What treats bcr-abl positive chronic myelogenous leukemia?
- Our catalog lists 5 products that may treat bcr-abl positive chronic myelogenous leukemia, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists; the current top-rated option is idarubicin hydrochloride.
- What is the best-rated treatment for bcr-abl positive chronic myelogenous leukemia?
- By our independent recall-safety rating — not an efficacy measure — idarubicin hydrochloride ranks highest among the products we list for bcr-abl positive chronic myelogenous leukemia. Always consult a professional.
- How are these treatments ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
- What types of drugs treat bcr-abl positive chronic myelogenous leukemia?
- Treatments for bcr-abl positive chronic myelogenous leukemia span FDA drug classes including anthracycline topoisomerase inhibitor, kinase inhibitor, alkylating drug. Compare every option side by side, ranked by independent rating, above.
Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.